For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 38,598 | 59,994* | 40,520 | - |
| General and administrative | 14,266 | 23,551* | 12,180 | - |
| Acquired in-process research and development | - | -10,000* | 5,000 | - |
| Total operating expenses | 52,864 | 73,545 | 57,700 | - |
| Loss from operations | -52,864 | -73,545* | -57,700 | -54,040 |
| Interest income | 1,231 | 1,976* | 1,685 | - |
| Interest expense | 1,854 | 978* | 747 | - |
| Other income (expense), net | 59 | -57* | 7 | -480 |
| Interest income, net | - | - | - | 1,814 |
| Total other income (expense) | -564 | 940* | 945 | 1,334 |
| Net loss before income taxes | -53,428 | -72,606* | -56,755 | -52,706 |
| Provision for income taxes | 30 | 93* | 0 | 25 |
| Net loss | -53,458 | -72,699* | -56,755 | -52,731 |
| Unrealized loss on marketable debt securities | 0 | -80* | 24 | -12 |
| Comprehensive loss | -53,458 | -72,779 | -56,731 | -52,743 |
| Basic EPS | -0.3 | -0.437 | -0.35 | -0.33 |
| Diluted EPS | -0.3 | -0.437 | -0.35 | -0.33 |
| Basic Average Shares | 179,872,000 | 166,644,000 | 161,838,000 | 161,691,000 |
| Diluted Average Shares | 179,872,000 | 166,644,000 | 161,838,000 | 161,691,000 |
Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics, Inc. (NMRA)